ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and…
Witness the power of advanced automation, multi-orbit connectivity and cloud-driven scalability in action HERNDON, Va., March 5, 2025 /PRNewswire/…
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…